The surgical extraction of the lower third molars is widely practiced in oral surgery. Subsequent inflammatory complications such as pain, facial swelling, and trismus can negatively affect the quality of life of the patients. Non-medication methods used to minimize tissue injury after third-molar extraction and without side effects include the use of photobiomodulation.
1. Introduction
The surgical extraction of the third mandibular molars is the most frequent procedure in oral and maxillo-facial surgery
[1].
An impacted third molar can cause different consequences such as pericoronitis, distal caries and periodontal pocket of the second molar, odontogenic abscesses, and the development of follicular cysts
[2].
The healing period following the surgical extraction of an impacted third mandibular molar is associated with an intense inflammatory response. This process is responsible for postoperative pain, facial swelling, and trismus, which negatively affect the quality of life of the patients during 7–10 days after the surgery
[3]. These signs and symptoms are a consequence of the surgical wound and the duration of the surgery itself
[4], as the result of a direct trauma on the blood and lymphatic vessels
[5]. After local anesthesia wears off, the pain usually reaches maximum intensity 3 to 5 h after surgery, continuing for 2 to 3 days, and gradually diminishing until the seventh day
[6][7]. Swelling reaches peak intensity in 12 to 48 h, influencing facial esthetics and social interactions. It usually resolves between the fifth and seventh days. Trismus may be considered initially as having a protective function by encouraging the patient to rest the surgical site and permit healing. However, it may lead to difficulty in eating and functioning if it persists for more than a few days.
Piezoelectric devices, which can be used instead of conventional burs, may be beneficial for surgeries at complex anatomical sites because they can preferentially cut mineralized structure
[8]; furthermore, some authors reported a reduction in postoperative sequelae using the piezoelectric surgical technique in third molar extraction
[9][10].
The standard therapeutic approach to reduce the postoperative complications is the administration of medications such as non-steroidal anti-inflammatories (FANS), corticosteroids (CS), and analgesics. However, even if they are effective, these drugs present some important adverse effects such as the tendency to systemic bleeding, gastrointestinal irritation, and allergic reactions. In addition, antibiotics reduce the risk of postoperative infection and alveolitis, but the possibility of developing bacterial resistance makes their administration indicated only in selected cases
[11].
These considerations justify the effort to find alternative and innovative methods for the resolution of the symptomatology that follows the surgical extraction of the impacted mandibular third molars, possibly without adverse effects. Non-medication methods used to minimize the postoperative after third molar extraction include cryotherapy, acupuncture, and photobiomodulation (PBM)
[12][13][14].
PBM is the application of near-infrared (NIR) light for therapeutic purpose. The “optical window” in which the effective penetration of light into tissues is maximized is between approximately 600 and 1200 nm. Low-energy laser light produces photochemical effects whereby it penetrates the mucosa without overheating or producing other side effects
[15].
In literature, the conclusions of the effectiveness of PBM after third molars surgical extractions are controversial. The current evidence on the effect of PBM on pain, swelling, and trismus after third molars surgery are summarized and reported.
2. Description of the Studies
A detailed flow chart of the selection process is shown in Figure 1.
Figure 1.
Flow chart illustrating the search strategy.
A total of 1833 subjects participated across the 41 studies. Nine studies did not record participants’ gender; in the other studies, there were 727 female participants and 1106 male participants.
The characteristics of the included studies are presented in Table 1 and Table 2.
Table 1. Characteristics of the included studies.
|
Authors and Year of Publication |
Laser Properties |
Outcomes |
Sample Size |
|
Table 2. Method of evaluation of the outcomes and main results of the included studies.
|
Method of Evaluation |
Comparison |
Results |
|
(nm) |
(mW) |
(J/cm | 2 | ) |
|
|
|
Asutay et al. (2018) | [16] |
810 |
300 |
4 |
pain, trismus, swelling |
Reduction |
Not statistically significant | 45 |
Not statistically significant |
|
Hamid et al. (2017) |
[17] | [17] |
810 |
100 |
32, 86 |
pain |
30 |
VAS |
vs. placebo |
Reduction |
|
|
|
Landucci et al. (2016) | [18] |
780 |
10 |
7, 5 |
pain, trismus, swelling |
[ | 22 |
18] |
VAS, NRS |
vs. placebo |
Not statistically significant |
Reduction |
Reduction |
|
Sierra et al. (2015) |
[19] | [19] |
660, 808 |
100 |
VAS, FDM, MO | 106 |
pain |
60 |
vs. placebo |
Reduction |
|
[20 | Sierra et al. (2016) | [20] |
660, 808 |
] | 100 |
106 |
FDM, MO |
808 nm vs. 660 nm |
|
808 Reduction | pain |
60 |
808 Reduction |
|
Pol et al. (2016) | [21] |
650, 904 |
8–500, 70 |
no reported |
pain, swelling |
25 |
[21] |
VAS, FDM |
vs. placebo |
Reduction |
Reduction |
|
|
Abdel-Alim et al. (2015) | [22] |
[22 | 830 |
] |
MO, Bello’s FSA | 4 |
no reported |
pain, trismus, swelling |
80 |
vs. delayed PBM |
Reduction |
Reduction |
Reduction |
|
Fabre et al. (2015) | [23] |
660 |
35 |
5 |
pain, trismus, swelling |
10 |
[23] |
VAS, FDM, MO |
vs. placebo |
Reduction |
Reduction |
Reduction |
|
[24 | Merigo et al. (2015) | [24] |
650, 910 |
] | no reported |
480, 31 |
pain, swelling |
59 |
VAS, FDM |
vs. placebo |
Reduction |
Reduction |
|
|
Ferrante et al. (2013) | [25] |
980 |
300 |
no reported |
pain, trismus, swelling |
30 |
[25] |
VAS, FDM, MO |
vs. placebo |
Reduction |
Reduction |
|
Koparal et al. (2018) | [26] |
810 |
300 |
4 |
pain, trismus, swelling |
45 |
Reduction |
[26] |
VAS, MO, 3dMD FP |
vs. placebo |
Reduction |
Not statistically significant |
Not statistically significant |
|
Raisesian et al. (2017) | [27] |
980 |
300 |
18 |
pain, trismus, swelling |
44 |
[27 |
|
Petrini et al. (2017) | [28] |
980 |
300 |
no reported |
pain, trismus, swelling |
45 |
] |
|
Kahraman et al. (2017) | [29] |
830 |
100 |
3 |
pain |
53 |
|
Alan et al. (2016) | [30] |
810 |
300 |
4 |
pain, trismus, swelling |
15 |
VAS, FDM, MO |
|
Eroglu et al. (2016) | [31] |
940 |
no reported |
4 |
pain, trismus, swelling |
35 |
vs. drug therapy |
Reduction |
Not statistically significant |
Not statistically significant |
[28] |
VAS, FDM, MO |
vs. drug therapy |
Reduction |
Reduction |
Not statistically significant |
[29] |
VAS |
intraoral vs. extraoral |
Reduction |
|
|
[30] |
VAS, MO, 3dMD FP |
vs. placebo |
Reduction |
Not statistically significant |
Not statistically significant |
[31] |
VAS, FDM, MO |
vs. placebo |
Not statistically significant |
Not statistically significant |
Not statistically significant |
|
[32 | Eshghpour et al. (2016) | [32] |
660 |
] | 200 |
85, 7 |
pain, swelling |
40 |
VAS, ECE |
vs. placebo |
|
Kazancioglu et al. (2014) | [33] |
808 |
100 |
4 |
pain, trismus, swelling |
60 |
Reduction |
Reduction |
|
[33] |
VAS, FDM, MO |
vs. ozone therapy |
Reduction |
Reduction |
|
Tuk et al. (2017) | [34] |
660 |
198 |
67,5 |
pain |
163 |
Reduction |
[34] |
HR, SR, Questionnaire |
vs. placebo |
Not statistically significant |
|
|
|
Farhadi et al. (2017) | [35] |
550 |
100 |
5 |
pain, trismus, swelling |
48 |
[35 |
|
Pedreira et al. (2016) | [36] |
808 |
no reported |
2 |
pain, trismus, swelling |
24 |
] | Not statistically significant |
|
Lopez Ramirez et al. (2012) | [37] |
810 |
500 |
[37] |
VAS, FDM, MO |
vs. placebo | 5 |
pain, trismus, swelling |
20 |
Not statistically significant |
Not statistically significant |
Not statistically significant |
|
Amarillas et al. (2010) | [38] |
810 |
c100 |
4 |
pain, trismus, swelling |
30 |
VAS, FDM, MO |
[38] |
VAS, FDM, MO |
vs. placebo |
Not statistically significant |
Not statistically significant |
Not statistically significant |
|
Roynesdal et al. (1993) | [39] |
830 |
40 |
no reported |
pain, trismus, swelling |
25 |
[39] |
VAS, FS, MO |
vs. placebo |
Not statistically significant |
Not statistically significant |
Not statistically significant |
|
Fernando et al. (1993) | [40] |
830 |
30 |
no reported |
pain, swelling |
52 |
vs. placebo |
[40] |
VAS, Swelling scale |
vs. placebo |
Not statistically significant |
Not statistically significant |
|
|
[41] | Markovic et al. (2007) | [41] |
637 |
50 |
4 |
swelling |
120 |
Not statistically significant |
FDM |
vs. placebo |
|
Reduction |
| 100 |
4 |
swelling, trismus |
32 |
[42] |
Amin Laskin FS, MO |
vs. placebo |
|
Reduction |
Reduction |
|
Aras et al. (2010) | [43] |
808 |
100 |
4 |
[43] |
Amin Laskin FS, MO | swelling, trismus |
48 |
Not statistically significant |
intraoral vs. extraoral |
|
Feslihan et al. (2019) | [44] |
810 |
300 |
6 |
pain, trismus, swelling |
30 |
|
Santos et al. (2020) | [45] |
780 |
70 |
52, 5 |
pain |
32 |
Not statistically significant |
[36] |
VAS, FDM, MO |
vs. placebo |
Not statistically significant |
Not statistically significant |
|
Aras et al. (2009) | [42] |
808 |
|
Reduction |
Reduction |
[44] |
VAS, FDM, MO |
vs. methylprednisolone |
Not statistically significant |
Not statistically significant |
Not statistically significant |
[45] |
VAS |
vs. split mouth |
Reduction |
|
|
|
Lakshmi et al. (2021) | [46] |
[ | 980 |
300 |
no reported |
46] | pain, trismus, swelling |
100 |
VAS, FS, MO |
vs. placebo |
Not statistically significant |
|
El Saeed et al. (2020) | [47] |
980 |
500 |
4 |
pain, trismus, swelling |
20 |
Reduction |
Reduction |
[47] |
VAS, FS, MO |
vs. placebo |
Reduction |
Reduction |
Reduction |
|
Nejat et al. (2021) | [48] |
660, 980 |
200 |
[48] | 1.5, 6 |
pain |
80 |
VAS |
vs. placebo |
Reduction |
|
|
|
Kamal et al. (2021) | [49] |
980 |
100 |
no reported |
pain, trismus, swelling |
[49 | 24 |
] |
VAS, FS, MO |
vs placebo |
Reduction |
Reduction |
Reduction |
|
Bianchi de Moraes et al. (2020) | [50] |
660 |
30 |
10, 30 |
pain, trismus, swelling |
57 |
[50] |
VAS, MO, 3dMD FP |
10 J/cm | 2 | vs. 30 J/cm | 2 | vs. placebo |
Not statistically significant |
|
Kumar Gulia et al. (2021) | [51] |
940 |
500 |
10 |
pain, trismus, swelling |
32 |
|
Scarano et al. (2021) | [52] |
1064 |
1000 |
no reported |
pain, swelling |
20 |
|
Momeni et al. (2021) | [53] |
940 |
500 |
10 |
pain, trismus, swelling |
25 |
|
Hadad et al. (2021) | [54] |
810 |
Fraga et al. (2020) | [55] |
808 |
100 |
133 |
[16] |
VAS, MO, 3dMD FP |
vs. placebo |
Not statistically significant |
Not statistically significant |
[ |
51 |
] |
VAS, FS, MO |
vs. placebo |
Reduction |
Not statistically significant |
Not statistically significant |
[ |
52 |
] |
VAS, FS |
vs. placebo |
Reduction |
Reduction |
|
[ |
53] |
VAS, FS, MO |
vs. placebo |
Reduction |
Not statistically significant |
Not statistically significant |
100 |
212 |
pain, trismus, swelling |
13 |
[54] |
VAS, FS, MO |
vs. placebo |
Reduction |
Reduction |
Not statistically significant |
|
[ | pain, swelling |
55] | 40 |
VAS, FS |
LLLT + aPDT vs. placebo |
Reduction |
Not statistically significant |
|
Mohajerani et al. (2020) | [56] |
810, 632 |
500 |
5, 2 |
pain, trismus, swelling |
40 |
[ |
56 |
] |
VAS, FS, MO |
vs. split mouth |
Reduction |
Reduction |
Not statistically significant |
3. Efficacy of PBM
3.1. Pain
Twenty-five studies reported a reduction of pain when compared to placebo
[16][17][19][21][22][23][24][25][26][27][28][29][30][32][33][45][46][47][51][52][53][54][55][56]. In these studies, lasers were used both intraorally and extraorally, and the laser’s parameters were as follows: wavelengths ranged from 632 to 1064 nm; powers were between 4 and 1000 mW; energy densities were between 3 and 212 J/cm
2. Eleven articles reported no statistically significant difference of PBM on reducing pain in comparison with placebo
[18][31][34][35][36][37][38][39][40]. The lasers used in these studies were diode lasers with wavelengths of 660 nm, 810 nm, and 980 nm, different powers (30–500 mW) and energy densities (2–60 J/cm
2). The most successful wavelengths in reducing pain were 810 and 980 nm (
Figure 2).
Figure 2. Histograms showing the pain outcome according to the wavelengths of the included studies. Legend: NR, no reduction, NSSR, no statistically significant results.
3.2. Facial Swelling
Facial swelling was assessed in 36 studies
[16][18][21][22][23][24][25][26][27][28][35][36][37][38][39][40][41][42][44][46][49][50][51][52][53][54][55][56]. Nineteen articles reported significant decrease in facial swelling after PBM application when compared with placebo
[18][20][21][22][23][24][25][32][33][41][42][43][46][47][49][52][54][56]. The laser’s parameters of the included articles were as follows: wavelengths ranged from 650 to 1064 nm; powers were between 4 and 1000 mW; energy densities were between 2 and 480 J/cm
2. The wavelength of 810 nm induced the smallest facial swelling reduction (
Figure 3).
Figure 3. Histograms showing the swelling outcome according to the wavelengths of the included studies. Legend: NR, no reduction, NSSR, no statistically significant results.
3.3. Trismus
Twenty-eight studies assessed the impact of PBM on postoperative trismus. Eleven studies reported reducing of trismus with PBM
[19][20][22][23][25][33][42][43][46][47][49]. In the included studies, wavelengths ranged between 660 and 980 nm, power ranged between 4 and 500 mW, and energy densities were between 4 and 212 J/cm
2. As for swelling, the wavelength of 810 nm was the one that induced the worst outcome. Instead, the wavelength of 980 nm determined the better reduction of trismus (
Figure 4).
Figure 4. Histograms showing the trismus outcome according to the wavelengths of the included studies. Legend: NR, no reduction, NSSR, no statistically significant results.